NXL — Nexalin Technology, Inc.

—
Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1527352 ·
Last close
$1.50
Market Cap
$1.85M
52W High
$33.60
52W Low
$1.31
ADV30
57,339
Next earnings
—
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 78,301 55,681 -2,609,297 -2,662,068 3,287,275 793,139 3,023,933
Jun 2026 12,161 8,897 -2,247,315 -2,239,170 3,004,179 1,004,958 1,484,756
Mar 2026 14,950 13,133 -2,119,902 -2,096,837 3,694,633 1,207,895 808,364
Dec 2025 171,895 150,866 -2,413,167 -2,376,546 4,635,319 654,783 887,333

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-6,128,895
Investing CF
$5,284,197
Financing CF
$1,418,336
CapEx
$-179,862
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.45
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-97,203,419
Inventory
$233,462
Receivables
$52,930
ST Investments
$0
EBIT TTM
$-9,126,015
Pretax Income TTM
$-8,988,864
Interest Exp TTM
—
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$217,155
EBITDA
$-9,080,485
Free Cash Flow
$-2,533,424
Enterprise Value
$89,515
Total Cash
$1,004,958
Total Debt
$0
Shares Out
1,236,560
Trailing EPS
$-13.69
Book Value
$5.86
ROE
-240.3%
ROA
-119.2%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 301,647 -8,390,881 -8,222,181 4,635,319 887,333 3,747,986 -4,957,658
Dec 2024 168,721 -7,754,646 -7,607,182 4,222,732 546,694 3,676,038 -3,944,390
Dec 2023 110,748 -5,696,296 -4,648,709 3,631,916 425,281 3,206,635 -3,835,384
Dec 2022 1,321,357 -1,833,031 -1,697,816 7,432,136 1,953,449 5,478,687 -2,215,699

TTM Snapshot

Revenues TTM
$217,155
NetIncome TTM
$-8,988,864
OpCashFlow TTM
—
Assets (Latest)
$3,004,179
Forward EPS
$-7.55

Peers — same industry

TickerNameMarket CapLastDaily %
CODX Co-Diagnostics, Inc. $2.06M $0.20 —
VVOS Vivos Therapeutics, Inc. $1.60M $0.08 —
AMIX Autonomix Medical, Inc. $2.21M $1.08 —
CUPR Cuprina Holdings (Cayman) LTD $1.56M $1.69 —
NUWE Nuwellis, Inc. $2.22M $4.10 —

News headlines (Yahoo Finance, 1h cache)

Nexalin Technology Announces Fourth Peer-Reviewed Publication in Alzheimer's Disease: 15 mA DIFS™ Significantly Improves Sleep Quality in Patients with Mild Alzheimer's Disease
2026-10-27 13:00 · Yahoo
Nexalin Technology Regains Compliance with Nasdaq Minimum Bid Price Requirement; Nasdaq Hearings Panel Grants Request for Continued Listing
2026-10-08 12:30 · Yahoo
Top Midday Gainers
2026-10-01 18:33 · Yahoo
Nexalin Technology Signs South America Distribution Agreement for Nexalin Sync Commercialization
2026-10-01 14:03 · Yahoo
Nexalin Technology Signs Definitive Exclusive Distribution and Local Manufacturing Agreement for Brazil and South America, Marking a Major Step in its Transition Toward Commercial Revenue Generation
2026-10-01 12:30 · Yahoo
Anixa Biosciences and Nexalin Technology Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV
2026-09-11 13:00 · Yahoo
Nexalin Technology Announces Reverse Stock Split
2026-08-27 11:25 · Yahoo
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
2026-04-22 13:35 · Yahoo
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
2026-04-28 13:15 · Yahoo
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
2026-06-10 13:01 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.